BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Phase 3positiveVOXZOGOPositive
AI Analysis
Summary
BioMarin announced positive Phase 3 CANOPY-HCH-3 results for VOXZOGO (vosoritide) in hypochondroplasia, demonstrating statistically significant improvements across multiple endpoints. Data were published in NEJM Evidence and presented at ESPE 2026.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Statistically significant improvements across multiple endpoints in CANOPY-HCH-3 study
Importance:8/10
Sentiment:
0.85
Phase 3 dataPositive resultsHypochondroplasiaNEJM publicationPediatric indicationESPE 2026
Related Companies
Read the original article
Published by PR Newswire Pharma on September 9, 2026 1:05 PM